论文部分内容阅读
目的探讨采用重组人干扰素α-1b高频雾化吸入治疗小儿病毒性上呼吸道感染的临床疗效。方法利用回顾性分析的方法研究和比较对本院于2010年1月1日~2013年10月31日期间收治的10例小儿病毒性上呼吸道感染患儿的临床资料进行回顾性对照分析。将患者随机分为两组,每组75例,对照组应用利巴韦林注射液进行治疗;观察组应用重组人干扰素α-1b高频雾化吸入进行治疗。然后将两组数据结果进行分析,分析探讨两组患者疗效的结果以及患儿家属满意度。结果观察组总有效率为90.67%,对照组总有效率为69.33%;观察组总满意率为97.33%,对照组总满意率为77.33%。观察组患者的治疗效果以及患儿家属总满意率显著好于对照组(P<0.05)。结论采用重组人干扰素α-1b高频雾化吸入治疗小儿病毒性上呼吸道感染患儿具有很好的临床疗效,对我国治疗小儿病毒性上呼吸道感染的发展具有重要价值,值得临床借鉴和进一步推广。
Objective To investigate the clinical efficacy of high-frequency aerosol inhalation of recombinant human interferon α-1b in the treatment of pediatric viral upper respiratory tract infection. Methods The retrospective analysis was used to study and compare the clinical data of 10 children with viral upper respiratory tract infection admitted to our hospital from January 1, 2010 to October 31, 2013. The patients were randomly divided into two groups, 75 cases in each group. The control group was treated with ribavirin injection. The observation group was treated with high-frequency inhalation of recombinant human interferon alpha-1b. Then two sets of data were analyzed, the results of two groups of patients were analyzed and their satisfaction with family members was analyzed. Results The total effective rate was 90.67% in the observation group and 69.33% in the control group. The total satisfaction rate was 97.33% in the observation group and 77.33% in the control group. The treatment effect of observation group patients and the total satisfaction rate of family members were significantly better than the control group (P <0.05). Conclusion The treatment of children with viral upper respiratory tract infection with recombinant human interferon α-1b by high-frequency atomized inhalation has good clinical curative effect and is of great value to the development of pediatric viral upper respiratory tract infection in our country, which is worthy of clinical reference and further Promotion.